Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.505
+0.035 (2.38%)
At close: Apr 23, 2025, 4:00 PM
1.520
+0.015 (1.00%)
After-hours: Apr 23, 2025, 5:26 PM EDT

Company Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.

The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia.

It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia.

The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Annovis Bio, Inc.
Annovis Bio logo
Country United States
Founded 2008
IPO Date Jan 29, 2020
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Maria Maccecchini

Contact Details

Address:
101 Lindenwood Drive, Suite 225
Malvern, Pennsylvania 19355
United States
Phone 484 875 3192
Website annovisbio.com

Stock Details

Ticker Symbol ANVS
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $6.00
CIK Code 0001477845
CUSIP Number 03615A108
ISIN Number US03615A1088
Employer ID 26-2540421
SIC Code 2834

Key Executives

Name Position
Dr. Maria L. Maccecchini Ph.D. Founder, Chief Executive Officer, President, Interim Principal Financial Officer and Executive Director
Mark K. White Chief Business Officer and Director
Dr. Cheng Fang Ph.D. Senior Vice President of Research and Development
Eve M. Damiano M.S., RAC Senior Vice President of Regulatory Operations
Melissa Gaines Senior Vice President of Clinical Operations
Blake Jensen Head of Quality
Hilda Maibach Senior Vice President of Statistics

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 21, 2025 10-K Annual Report
Mar 21, 2025 8-K Current Report
Feb 10, 2025 SCHEDULE 13G Filing
Feb 5, 2025 8-K Current Report
Feb 5, 2025 8-K Current Report
Feb 4, 2025 424B5 Filing
Feb 3, 2025 424B5 Filing
Dec 11, 2024 8-K Current Report
Dec 11, 2024 8-K Current Report